An exceptionally potent analog of sandramycin

The preparation and preliminary evaluation of 2, an analog of sandramycin, are detailed. Although 2 was typically 4–10x less potent than sandramycin against leukemia cell lines, it was found to be 1–10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting typical IC50 values of 200-1 pM and placing it among the most potent agents identified to date.